A longitudinal study of streptococcus pneumoniae carriage in healthy children in the 13-valent pneumococcal conjugate vaccine era

References

• Lynch JP, Zhanel GG. Streptococcus pneumoniae: epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines. Curr Opin Pulm Med 2010; 16:217-25; PMID:20375783
   PubMed Web of Science ®Google Scholar
• Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennet MN, Reingold A, Thomas A, Schaffner W, Craig AS, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010; 201:32-41; PMID:19947881; http://dx.doi.org/10.1086/648593
   PubMed Web of Science ®Google Scholar
• Rodenburg GD, Greeff SC de, Jansen AGCS, Melker HE de, Schouls LM, Hak E, Spanjaard L, Sanders EA, van der Ende A. Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands. Emerg Infect Dis 2010; 16:816-823.
   Google Scholar
• Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, Reingold A, Cieslak PR, Pilishvili T, Jackson D, et al. Active bacterial core surveillance of the emerging infections program network: decline in invasive pneumococcal disease after the introduction of protein polysaccharide conjugate vaccine. N Engl J Med 2003; 348:1737-46; PMID:12724479; http://dx.doi.org/10.1056/NEJMoa022823
   PubMed Web of Science ®Google Scholar
• Dagan R, Melamed R, Muallem M, Piglansky L, Greenberg D, Abramsom O, Mendelman PM, Bohidar N, Yagupsky P. Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine. J Infect Dis 1996; 174:1271-1278; PMID:8940218; http://dx.doi.org/10.1093/infdis/174.6.1271
   PubMed Web of Science ®Google Scholar
• Rose M, Zielen S. Impact of infant immunization programs with pneumococcal conjugate vaccine in Europe. Expert Rev Vaccines 2009; 8:1351-64; PMID:19803758; http://dx.doi.org/10.1586/erv.09.78
   PubMed Web of Science ®Google Scholar
• Pelton SI, Huot H, Finkelstein JA, Bishop CJ, Hsu KK, Kellembrg J, Huang SS, Goldstein R, Hanage WP. Emergence of 19A as virulent and multidrug resistant Pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr Infect Dis J 2007; 26:468-472; PMID:17529860; http://dx.doi.org/10.1097/INF.0b013e31803df9ca
   PubMed Web of Science ®Google Scholar
• Huang SS, Hinrichsen VL, Stevenson AE, Rifas-Shiman SL, Kleinman K, Pelton SI, Lipsitch M, Hanage WP, Lee GM, Finkelstein JA. Continued impact of pneumococcal conjugate vaccine on carriage in young children. Pediatrics. 2009; 124:e1-11; PMID:19564254; http://dx.doi.org/10.1542/peds.2008-3099
   PubMedGoogle Scholar
• Vestrheim DF, Høiby EA, Aaberge IS, Caugant DA. Impact of a pneumococcal conjugate vaccination program on carriage among children in Norway. Clin Vaccine Immunol 2010; 17:325-334; PMID:20107006; http://dx.doi.org/10.1128/CVI.00435-09
   PubMed Web of Science ®Google Scholar
• Kaplan SL, Barson WJ,, Lin PL,, Romero JR,, Bradley JS,, Tan TQ,, Hoffman JA,, Givner LB,, Mason EO, Jr. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2013; 32:203-207; PMID:23558320; http://dx.doi.org/10.1097/INF.0b013e318275614b
   PubMed Web of Science ®Google Scholar
• Moore M, Link-Gelles R, Farley MM, Schaffner W, Thomas A, Reingold A, Harrison L, Lexau C, Zansky S, Petit S, et al. Impact of 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease, U.S, 2010-11. [ID Week 2012, San Diego, CA, October 17-21, 2012]. 2012. Available at: https://idsa.confex.com/idsa/2012/webprogram/Paper36569.html. Accessed at 15 September 2014.
   Google Scholar
• Demczuk WH, Martin I, Griffith A, Lefebvre B, McGeer A, Lovgren M, Tyrrell GJ, Desai S, Sherrard L, Adam H, et al. Toronto Bacterial Diseases Network; Canadian Public Health Laboratory Network. Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010-2012. Can J Microbiol. 2013;59:778-788; PMID:24313450; http://dx.doi.org/10.1139/cjm-2013-0614
   PubMed Web of Science ®Google Scholar
• Moore CE, Paul J, Foster D, Mahar SA, Griffiths D, Knox K, Peto TE, Walker AS, Crook DW, on behalf of the Oxford Invasive Pneumococcal Surveillance Group. Reduction of invasive pneumococcal disease three years after the introduction of the 13 valent conjugate vaccine in the Oxfordshire region, England. J Infect Dis 2014; 210:1001-1011; PMID:24719477; http://dx.doi.org/10.1093/infdis/jiu213
   PubMed Web of Science ®Google Scholar
• Levy C, Varon E, Picard C, Béchet S, Martinot A, Bonacorsi S, Cohen R. Trends of pneumococcal meningitis in children after introduction of the 13-Valent pneumococcal conjugate vaccine in France. PediatrInfect Dis J 2014; 33:1216-21; PMID:25037044; http://dx.doi.org/10.1097/INF.0000000000000451
   PubMed Web of Science ®Google Scholar
• Guevara M, Ezpeleta C, Gil-Setas A, Torroba L, Beristain X, Aguinaga A, García-Irure JJ, Navascués A, García-Cenoz M, Castilla J, Working Group for Surveillance of the Pneumococcal Disease in Navarre. Reduced incidence of invasive pneumococcal disease after introduction of the 13-valent conjugate vaccine in Navarre, Spain, 2001-2013. Vaccine 2014; 32:2553-2562; PMID:24674661; http://dx.doi.org/10.1016/j.vaccine.2014.03.054
   PubMed Web of Science ®Google Scholar
• Georgakopoulou T, Menegas D, Tzanakaki G, Pipa E, Vernardaki A, Mavraganis P, Theodoridou M, Kremastinou J. Epidemiology of Bacterial Meningitis in Greece, in the Era of Conjugate Vaccines: A 7 Years Review 2005-2011. 52nd ICAAC, San Francisco, CA, USA, September 9-12 2012. Available at: http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=d201a978-86b7-4126-b4ebdce82709451f&cKey=fd9b920f-2dad-4c23-9dba-3f0f20b33da8&mKey=%7b6B114A1D-85A4-4054-A83B-04D8B9B8749F%7d. Accessed June 13, 2014.
   Google Scholar
• van der Linden M, von Kries R, Imohl M. Effects of three years of immunization with higher valent pneumococcal conjugate vaccines on serotype distributions among reported IPD cases in German children and adults. Presented at 52nd ICAAC, September 9-12, 2012, San Francisco. September 10, 2012. Available at: http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=becf1b8c-545a-4792-ac02-4a9cb31fdf7b&cKey=bb809851-e003-4b87-8957-043e6ed60add&mKey=%7b6B114A1D-85A4-4054-A83B-04D8B9B8749F%7d. Accessed June 8, 2014.
   Google Scholar
• Angoulvant F, Levy C, Grimprel E, Varon E, Lorrot M, Biscardi S, Minodier P, Dommergues MA, Hees L, Gillet Y, at al. Early impact of 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in children. Clin Infect Dis 2014; 58:918-924; PMID:24532543; http://dx.doi.org/10.1093/cid/ciu006
   PubMed Web of Science ®Google Scholar
• Ben-Shimol S, Givon-Lavi N, Leibovitz E, Raiz S, Greenberg D, Dagan R. Near elimination of otitis media caused by the PCV13 serotypes in Southern Israel shortly after sequential introduction of PCV7/PCV13. Clin Infect Dis 2014; 59:1724-32; PMID:25159581; http://dx.doi.org/10.1093/cid/ciu683
   PubMed Web of Science ®Google Scholar
• Azzari C, Martinón-Torres F, Schmitt HJ, Dagan R. Evolving role of 13-Valent pneumococcal conjugate vaccine in clinical practice. Pediatr Infect Dis J 2014; 33:858-864; PMID:24618937; http://dx.doi.org/10.1097/INF.0000000000000328
   PubMed Web of Science ®Google Scholar
• Camilli R, Daprai L, Cavrini F, Lombardo D, D'Ambrosio F, Del Grosso M, Vescio MF, Landini MP, Pascucci MG, Torresani E, et al. Pneumococcal carriage in young children one year after introduction of the 13-valent conjugate vaccine in Italy. PLoS One 2013;8:e76309; PMID:24124543; http://dx.doi.org/10.1371/journal.pone.0076309
   PubMedGoogle Scholar
• Dagan R, Patterson S, Juergens C, Greenberg D, Givon-Lavi N, Porat N, Gurtman A, Gruber WC, Scott DA. Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial. Clin Infect Dis 2013; 57:952-62; PMID:23804191; http://dx.doi.org/10.1093/cid/cit428
   PubMed Web of Science ®Google Scholar
• Cohen R, Levy C, Bingen E, Koskas M, Nave I, Varon E. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media. Pediatr Infect Dis J 2012; 31:297-301; PMID:22330166; http://dx.doi.org/10.1097/INF.0b013e318247ef84
   PubMed Web of Science ®Google Scholar
• Loughlin AM, Hsu K, Silverio AL, Marchant CD, Pelton SI. Direct and indirect effects of PCV13 on nasopharyngeal carriage of PCV13 unique pneumococcal serotypes in massachusetts' children. Pediatr Infect Dis J 2014; 33:504-510; PMID:24670957; http://dx.doi.org/10.1097/INF.0000000000000279
   PubMed Web of Science ®Google Scholar
• van Hoek AJ, Sheppard CL, Andrews NJ, Waight PA, Slack MP, Harrison TG, Ladhani SN, Miller E. Pneumococcal carriage in children and adults two years after introduction of the thirteen valent pneumococcal conjugate vaccine in England. Vaccine 2014; 32:4349-4355; PMID:24657717; http://dx.doi.org/10.1016/j.vaccine.2014.03.017
   PubMed Web of Science ®Google Scholar
• Lee GM, Kleinman K, Pelton SI, Hanage W, Huang SS, Lakoma M, Dutta-Linn M, Croucher NJ, Stevenson A, Finkelstein JA. Impact of 13-valent pneumococcal conjugate caccination on streptococcus pneumoniae carriage in young children in Massachusetts. J Pediatric Infect Dis Soc 2014; 3:23-32; PMID:24567842; http://dx.doi.org/10.1093/jpids/pit057
   PubMedGoogle Scholar
• Gounder PP, Bruce MG, Bruden DJ, Singleton RJ, Rudolph K, Hurlburt DA,, Hennessy TW, Wenger J. Effect of the 13-Valent pneumococcal conjugate vaccine on nasopharyngeal colonization by streptococcus pneumoniae-Alaska, 2008-2012. J Infect Dis 2014; 209:1251-1258; PMID:24273178; http://dx.doi.org/10.1093/infdis/jit642
   PubMed Web of Science ®Google Scholar
• Zuccotti G, Mameli C, Daprai L, Garlaschi ML, Dilillo D, Bedogni G, Faccini M, Gramegna M, Torresani E; PneuMi Study Group (PMSG), et al. Serotype distribution and antimicrobial susceptibilities of nasopharyngeal isolates of Streptococcus pneumoniae from healthy children in the 13-valent pneumococcal conjugate vaccine era. Vaccine 2014; 32:527-534; PMID:24342249; http://dx.doi.org/10.1016/j.vaccine.2013.12.003
   PubMed Web of Science ®Google Scholar
• Ricketson LJ, Wood ML, Vanderkooi OG, MacDonald JC, Martin IE, Demczuk WH, Kellner JD; Calgary Streptococcus pneumoniae Epidemiology Research (CASPER) investigators. Trends in asymptomatic nasopharyngeal colonization with streptococcus pneumoniae after introduction of the 13-valent pneumococcal conjugate vaccine in Calgary, Canada. Pediatr Infect Dis J 2014; 33:724-30; PMID:24463806; http://dx.doi.org/10.1097/INF.0000000000000267
   PubMed Web of Science ®Google Scholar
• Bogaert D, de Groot R, Hermans PW. Streptococcus pneumoniae colonization: the key to pneumococcal disease. Lancet Infect Dis 2004; 4:144-54; PMID:14998500; http://dx.doi.org/10.1016/S1473-3099(04)00938-7
   PubMed Web of Science ®Google Scholar
• Mavroidi A, Aanensen DM, Godoy D, Skovsted IC,, Kaltoft MS, Reeves PR, Bentley SD, Spratt BG. Genetic relatedness of the Streptococcus pneumoniae capsular biosynthetic loci. J Bacteriol 2007; 189:7841-55; PMID:17766424; http://dx.doi.org/10.1128/JB.00836-07
   PubMedGoogle Scholar
• Steens A, Bergsaker MA, Aaberge IS, Rønning K, Vestrheim DF. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. Vaccine 2013; 31:6232-6238; PMID:24176490; http://dx.doi.org/10.1016/j.vaccine.2013.10.032
   PubMed Web of Science ®Google Scholar
• Fleming-Dutra K, Mbaeyi C, Link-Gelles R, Alexander N, Guh A, Forbes E, Beall B, Winchell JM, Carvalho Mda G, Pimenta F, Kodani M, et al. Streptococcus pneumoniae serotype 15A in psychiatric unit, Rhode Island, USA, 2010-2011. Emerg Infect Dis 2012; 18:1889-93; PMID:23092658; http://dx.doi.org/10.3201/eid1811.120454
   PubMedGoogle Scholar
• Parra EL, De La Hoz F, Díaz PL, Sanabria O, Realpe ME, Moreno J. Changes in Streptococcus pneumoniae serotype distribution in invasive disease and nasopharyngeal carriage after the heptavalent pneumococcal conjugate vaccine introduction in Bogotá, Colombia. Vaccine 2013; 31:4033-4038; PMID:23680440; http://dx.doi.org/10.1016/j.vaccine.2013.04.074
   PubMed Web of Science ®Google Scholar
• Martin JM, Hoberman A, Paradise JL, Barbadora KA, Shaikh N, Bhatnagar S, Shope T, Block SL, Haralam MA, et al. Emergence of streptococcus pneumoniae serogroups 15 and 35 in nasopharyngeal cultures from young children with Acute Otitis Media. Pediatr Infect Dis J 2014; 33:e286-90; PMID:24911895
   PubMed Web of Science ®Google Scholar
• O’Brien KL, Nohynek H, World Health Organization Pneumococcal Vaccine Trials Carriage Working Group. Report from a WHO working group: standard method for detecting upper respiratory carriage of Streptococcus pneumoniae. Pediatr Infect Dis J 2003; 22:133-40; PMID:12586987
   PubMed Web of Science ®Google Scholar
• Rabe-Hesketh S, Skrondal A. Multilevel and Longitudinal Modeling Using Stata, 3rd Edition. College Station: Stata Press; 2012.
   Google Scholar
• Skrondal A, Rabe-Hesketh S. Generalized latent variable modeling: multilevel, longitudinal, and structural equation models. Boca Raton: Chapman & Hall; 2004.
   Google Scholar
• Williams R. Using the margins command to estimate and interpret adjusted predictions and marginal effects. Stata J 2012; 12:308-331.
   Web of Science ®Google Scholar
• Cummings P. Methods for estimating adjusted risk ratios. Stata J 2009; 9:175-96.
   Web of Science ®Google Scholar